Premium
Endometrial carcinoma in the south of Israel: Study of 231 cases
Author(s) -
Piura Benjamin,
BarDayan Avner,
Cohen Yoram,
YanaiInbar Ilana,
Glezerman Marek
Publication year - 1997
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/(sici)1096-9098(199711)66:3<189::aid-jso7>3.0.co;2-8
Subject(s) - medicine , carcinoma , general surgery , gynecology , oncology
Background and Objectives Endometrial carcinoma is the commonest female genital tract malignancy in the south of Israel. The purpose of this study was to investigate the clinical and histologic findings, treatment and outcome of patients with endometrial carcinoma in the south of Israel. Methods Data from the files of 231 patients with endometrial carcinoma who were managed at the Soroka Medical Center between January 1961 and December 1994 were evaluated. Results Endometrial carcinoma was more prevalent among Jewish as compared to Arab‐Beduin women, and among Ashkenazi as compared to Sephardic Jewish women. The prevailing presenting symptom was postmenopausal bleeding and most patients (68.8%) had Stage I disease. Most patients (209/225, 92.9%) underwent surgery, 131/222 (59%) had radiotherapy and 15/214 (7%) received chemotherapy. The 5‐year survival rate was 79.1% overall; 89% for Stage I, 71.7% for Stage II, 21.6% for Stage III and 0% for Stage IV; 89.8% for Grade 1, 70% for Grade 2 and 60.9% for Grade 3; 100% for adenoacanthoma, 82% for endometrioid carcinoma, 65.8% for adenosquamous carcinoma and 51.6% for papillary serous carcinoma. Conclusions Endometrial carcinomas are characterized by a relatively favorable prognosis with a 5‐year survival of about 80%. Surgical stage, histologic differentiation and histologic subtype are sensitive predictors of survival. The mainstay of treatment is surgery with adjuvant pelvic radiotherapy when necessary. J. Surg. Oncol. 1997;66:189–195. © 1997 Wiley‐Liss, Inc.